University of Massachusetts Medical School Faculty Publications
Title
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
UMMS Affiliation
Department of Medicine, Division of Hematology/Oncology
Publication Date
2013-4
Document Type
Article
Subjects
Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; effects; Bleomycin; Dacarbazine; Doxorubicin; Etoposide; Female; Hematologic Diseases; Hodgkin Disease; Humans; Lung Diseases; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Prednisone; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine
Disciplines
Clinical Epidemiology | Hematology | Hemic and Lymphatic Diseases | Oncology
Abstract
There is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) and Stanford V (SV; doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone) regimens in older Hodgkin lymphoma (HL) patients. Forty-four advanced-stage, older HL patients (aged >/=60 years) were treated on the randomized study, E2496. Toxicities were mostly similar between chemotherapy regimens, although 24% of older patients developed bleomycin lung toxicity (BLT), which occurred mainly with ABVD (91%). Further, the BLT-related mortality rate was 18%. The overall treatment-related mortality for older HL patients was 9% vs. 0.3% for patients aged (P < 0.001). Among older patients, there were no survival differences between ABVD and SV. According to age, outcomes were significantly inferior for older versus younger patients (5-year failure-free survival: 48% vs. 74%, respectively, P = 0.002; 5-year overall survival: 58% and 90%, respectively, P < 0.0001), although time-to-progression (TTP) was not significantly different (5-year TTP: 68% vs. 78%, respectively, P = 0.37). Furthermore, considering progression and death without progression as competing risks, the risk of progression was not different between older and younger HL patients (5 years: 30% and 23%, respectively, P = 0.30); however, the incidence of death without progression was significantly increased for older HL patients (22% vs. 9%, respectively, P < 0.0001). Altogether, the marked HL age-dependent survival differences appeared attributable primarily to non-HL events.
DOI of Published Version
10.1111/bjh.12222
Source
Br J Haematol. 2013 Apr;161(1):76-86. doi: 10.1111/bjh.12222. Epub 2013 Jan 29. Link to article on publisher's site
Related Resources
Journal/Book/Conference Title
British journal of haematology
PubMed ID
23356491
Repository Citation
Evens A, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ. (2013). The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. University of Massachusetts Medical School Faculty Publications. https://doi.org/10.1111/bjh.12222. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/105